Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008

Background: Systemic fungal infections and specifically invasive aspergillosis (IA) are associated with a high morbi-mortality rate in patients with hematologic malignancies. Itraconazole kinetic studies show that plasma levels are not satisfactory, even though there is a reduction of the severity i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrade M,Alejandro, Puga L,Barbara, Guerra C,Carolina, Molina E,Javiera, Capurro C,Marisa
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2011
Materias:	Aspergillosis Itraconazole Leukemia lymphoid Leukemia, myeloid Mycoses fungoides
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000900003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872011000900003
record_format	dspace
spelling	oai:scielo:S0034-988720110009000032011-11-17Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008Andrade M,AlejandroPuga L,BarbaraGuerra C,CarolinaMolina E,JavieraCapurro C,Marisa Aspergillosis Itraconazole Leukemia lymphoid Leukemia, myeloid Mycoses fungoides Background: Systemic fungal infections and specifically invasive aspergillosis (IA) are associated with a high morbi-mortality rate in patients with hematologic malignancies. Itraconazole kinetic studies show that plasma levels are not satisfactory, even though there is a reduction of the severity in clinical cases. Aim: To evaluate the results of oral prophylaxis with high dose itraconazole, 400 mg bid, among patients with adult acute leukemia. Material and Methods: Prospective analysis of 93 high risk febrile episodes (with an absolute neutrophil count of less than 500 x mm3 for more 10 days), that occurred in 76 patients. Results: Seventy five percent of episodes occurred in patients with acute myeloid leukemia and 25% in patients with acute lymphoblastic leukemia. Fifty two percent occurred during the induction of chemotherapy. Median duration of severe neutropenia was 21 days (range 10-48). Median duration of itraconazole prophylaxis was 17 days (range 6-34). A low frequency of invasive fungal infections was observed (17%). According to diagnostic criteria, 5% of episodes corresponded to persistent fever , 1% and 11% of episodes, to probable or possible IA, respectively. No confirmed or proven IA was observed. Mortality of IA was 18%. No serious adverse events due to itraconazole were observed. Conclusions: The use of high dose itraconazole prophylaxis in adult patients with acute leukemia and severe neutropenia was associated to low incidence and mortality of invasive mycoses.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.139 n.9 20112011-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000900003es10.4067/S0034-98872011000900003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Aspergillosis Itraconazole Leukemia lymphoid Leukemia, myeloid Mycoses fungoides
spellingShingle	Aspergillosis Itraconazole Leukemia lymphoid Leukemia, myeloid Mycoses fungoides Andrade M,Alejandro Puga L,Barbara Guerra C,Carolina Molina E,Javiera Capurro C,Marisa Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008
description	Background: Systemic fungal infections and specifically invasive aspergillosis (IA) are associated with a high morbi-mortality rate in patients with hematologic malignancies. Itraconazole kinetic studies show that plasma levels are not satisfactory, even though there is a reduction of the severity in clinical cases. Aim: To evaluate the results of oral prophylaxis with high dose itraconazole, 400 mg bid, among patients with adult acute leukemia. Material and Methods: Prospective analysis of 93 high risk febrile episodes (with an absolute neutrophil count of less than 500 x mm3 for more 10 days), that occurred in 76 patients. Results: Seventy five percent of episodes occurred in patients with acute myeloid leukemia and 25% in patients with acute lymphoblastic leukemia. Fifty two percent occurred during the induction of chemotherapy. Median duration of severe neutropenia was 21 days (range 10-48). Median duration of itraconazole prophylaxis was 17 days (range 6-34). A low frequency of invasive fungal infections was observed (17%). According to diagnostic criteria, 5% of episodes corresponded to persistent fever , 1% and 11% of episodes, to probable or possible IA, respectively. No confirmed or proven IA was observed. Mortality of IA was 18%. No serious adverse events due to itraconazole were observed. Conclusions: The use of high dose itraconazole prophylaxis in adult patients with acute leukemia and severe neutropenia was associated to low incidence and mortality of invasive mycoses.
author	Andrade M,Alejandro Puga L,Barbara Guerra C,Carolina Molina E,Javiera Capurro C,Marisa
author_facet	Andrade M,Alejandro Puga L,Barbara Guerra C,Carolina Molina E,Javiera Capurro C,Marisa
author_sort	Andrade M,Alejandro
title	Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008
title_short	Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008
title_full	Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008
title_fullStr	Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008
title_full_unstemmed	Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008
title_sort	resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: hospital del salvador 2006-2008
publisher	Sociedad Médica de Santiago
publishDate	2011
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000900003
work_keys_str_mv	AT andrademalejandro resultadosdeprofilaxisconitraconazol800mgdiaviaoralenadultosconleucemiaagudayneutropeniadealtoriesgohospitaldelsalvador20062008 AT pugalbarbara resultadosdeprofilaxisconitraconazol800mgdiaviaoralenadultosconleucemiaagudayneutropeniadealtoriesgohospitaldelsalvador20062008 AT guerraccarolina resultadosdeprofilaxisconitraconazol800mgdiaviaoralenadultosconleucemiaagudayneutropeniadealtoriesgohospitaldelsalvador20062008 AT molinaejaviera resultadosdeprofilaxisconitraconazol800mgdiaviaoralenadultosconleucemiaagudayneutropeniadealtoriesgohospitaldelsalvador20062008 AT capurrocmarisa resultadosdeprofilaxisconitraconazol800mgdiaviaoralenadultosconleucemiaagudayneutropeniadealtoriesgohospitaldelsalvador20062008
_version_	1718436585339355136

Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008

Ejemplares similares